Sign inJoin waitlistJoin the waitlist

Praful Ravi

Assistant Professor of Medicine, Harvard Medical School · Mass General Brigham

Credentials: · · · · ·

History

Mass General Brigham
Present

Dana-Farber Cancer Institute
2018–2020
Internal Medicine
Mayo Clinic
2015–2018
CAMBRIDGE UNIV, CAMBRIDGE
2008–2012

Research

Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample
European Urology · 2012 · 331 citations
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate
European Urology · 2015 · 219 citations
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma
JAMA Oncology · 2020 · First of 17 authors · 114 citations

Quoc-Dien Trinh
32 papers · 23 as a fellow
Jesse Sammon
20 papers · 20 as a resident
CS
Christopher Sweeney
18 papers
Mani Menon
17 papers · 14 as a resident
Heather Jacene
16 papers
Bradley McGregor
15 papers
ShyamSunder Sukumar
14 papers · 13 as a resident
Toni Choueiri
14 papers
Adam Kibel
13 papers
GS
Guru Sonpavde
11 papers
Paul Nguyen
11 papers
Charlene Mantia
10 papers · 2 as a fellow

Clinical trials

177LuPSMA in Renal Cell Carcinoma
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2025–2028
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Principal investigator · Active not recruiting · Phase 1
Dana-Farber Cancer Institute
2024–2027
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Principal investigator · Completed · Phase 1
Praful Ravi, MB BCHir, MRCP
2023–2026
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
Site PI · Recruiting · Phase 2
Convergent Therapeutics
2024–2027